COVID-19 has presented new, previously unimaginable challenges to all aspects of our global community, not least our health care systems. The pandemic has impacted almost every part of health care delivery – with new strategies to manage unprecedented patient numbers, elective surgery and equipment supply chains, and the increased use of e-health and virtual care.
For the pharma and biotech sectors, this has meant adapting many long-standing operational practices and responding with agility in a...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?